Related references
Note: Only part of the references are listed.Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis
Yee-Ming Melody Cheung et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Delayed immune-related adverse events with an PD-1-based immunotherapy in melanoma
C. N. Owen et al.
ANNALS OF ONCOLOGY (2021)
Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment
Christopher A. Muir et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study
Pei Yi Lee et al.
CANCERS (2021)
Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers
Anupam Kotwal et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2021)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R. Brahmer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment
Christopher A. Muir et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Fausto Petrelli et al.
JOURNAL OF IMMUNOTHERAPY (2020)
Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management
Jaydira Del Rivero et al.
ONCOLOGIST (2020)
Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma
Kazuo Kobayashi et al.
ONCOLOGY (2020)
Endocrine adverse events related to immune-oncology agents: retrospective experience of a single institution
Sofia Espana et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients
Edwin A. Basak et al.
THYROID (2020)
Strategies for improving the management of immune-related adverse events
Aung Naing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Jeroen de Filette et al.
HORMONE AND METABOLIC RESEARCH (2019)
Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients.
Roy Elias et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Management of Immunotherapy-Related Toxicities. Version 1.2019
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
V. Ellen Maher et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab
Ichiro Yamauchi et al.
PLOS ONE (2019)
Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
Jeroen M. K. de Filette et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: updates diagnostic hazard of autoimmunity at a distance
Marcus A. Couey et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Evaluation of Thyroid Hormone Replacement Dosing in Overweight and Obese Patients After a Thyroidectomy
Vardan Papoian et al.
THYROID (2019)
Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors
Sophia C. Weinmann et al.
RHEUMATOLOGY (2019)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
Biagio Ricciuti et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
Takeo Fujii et al.
INVESTIGATIONAL NEW DRUGS (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis
Romualdo Barroso-Sousa et al.
JAMA ONCOLOGY (2018)
Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).
Mariona Riudavets et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
Priyanka C. Iyer et al.
THYROID (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management
Monica Girotra et al.
JNCI CANCER SPECTRUM (2018)
Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study
Tomoko Kobayashi et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2018)
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J. C. Osorio et al.
ANNALS OF ONCOLOGY (2017)
Endocrine side effects of cancer immunotherapy
Priscilla Cukier et al.
ENDOCRINE-RELATED CANCER (2017)
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
Danae A. Delivanis et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
Shunsuke Teraoka et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
Hyunju Lee et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma
D. L. Morganstein et al.
CLINICAL ENDOCRINOLOGY (2017)
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
Alexander Faje
PITUITARY (2016)
Hypophysitis
Hidenori Fukuoka
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2015)
Diagnosis of Primary Hypophysitis in Germany
Juergen Honegger et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study
Le Min et al.
CLINICAL CANCER RESEARCH (2015)
Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma
Frederique Albarel et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
Alexander T. Faje et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
Shintaro Iwama et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Levothyroxine replacement dosage determination after thyroidectomy
Judy Jin et al.
AMERICAN JOURNAL OF SURGERY (2013)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Tumor Immunotherapy Directed at PD-1
Antoni Ribas
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
Padmanee Sharma et al.
NATURE REVIEWS CANCER (2011)
Share Paper
